(Project 2) The overarching goal of this project is to study key features of epigenetic circuitry in MM, with the objective of improving our understanding of global gene regulation in this cancer, and with the goal of deploying novel therapeutics that target key epigenomic circuits in MM as dependencies. Cells and cell states can be defined by their gene expression programs, and tumor cells commonly have deregulated gene expression programs. The production of a gene expression program is accomplished by the cell?s epigenetic apparatus. It is now possible, for any normal or cancer cell type, to identify the master transcription factors, the enhancer elements they occupy, and the genes they regulate, and thus to develop a testable model of this genome-wide epigenetic circuitry. Furthermore, it is possible to identify the gene regulatory elements on which the cell is most dependent, and thus identify the portions of the circuitry on which a cancer cell is most dependent. Tumor cells tend to develop striking dependencies on super-enhancer regulatory elements (3-6). Recent studies suggest that the transcriptional cofactors BRD4, CDK7 and CDK12 play especially important roles in tumor cell epigenetic circuitry, and their inhibition with small molecules can cause a loss of super-enhancer domains that drive genes with prominent roles in tumorigenesis (3-6). We propose to decipher the key features of MM epigenetic circuitry, to identify the features that confer great dependency, and to investigate the potential of small molecule inhibitors to disrupt those dependencies in MM. To accomplish these goals, the specific aims of the proposal are 1) To discover key features of epigenomic circuitry in multiple myeloma by integrated epigenomic analysis, 2) to determine epigenetic dependencies in multiple myeloma using gene editing approaches, and 3) to explore the ability of small molecule inhibitors of transcriptional cofactors to disrupt key nodes in multiple myeloma epigenetic circuitry.

Public Health Relevance

(Project 2) The overarching goal of this project is to study key features of epigenetic circuitry in Multiple Myeloma (MM), with the objective of improving our understanding of global gene regulation in this cancer, and with the goal of deploying novel therapeutics that target key epigenomic circuits in MM as dependencies. We propose to decipher key features of MM epigenetic circuitry, to identify features that confer greatest dependency, and to investigate the potential of small molecule inhibitors to disrupt those dependencies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA155258-08
Application #
9788060
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-08-01
Budget End
2020-07-31
Support Year
8
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Zeid, Rhamy; Lawlor, Matthew A; Poon, Evon et al. (2018) Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. Nat Genet 50:515-523
Maura, F; Petljak, M; Lionetti, M et al. (2018) Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia 32:1044-1048
Bae, J; Hideshima, T; Zhang, G L et al. (2018) Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma. Leukemia 32:752-764
O'Donnell, Elizabeth K; Laubach, Jacob P; Yee, Andrew J et al. (2018) A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol 182:222-230
Guo, Guangwu; Raje, Noopur S; Seifer, Charles et al. (2018) Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia 32:1838-1841
Szalat, R; Samur, M K; Fulciniti, M et al. (2018) Nucleotide excision repair is a potential therapeutic target in multiple myeloma. Leukemia 32:111-119
Nair, Shiny; Sng, Joel; Boddupalli, Chandra Sekhar et al. (2018) Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight 3:
Gullà, A; Hideshima, T; Bianchi, G et al. (2018) Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia 32:996-1002
Mazzotti, Céline; Buisson, Laure; Maheo, Sabrina et al. (2018) Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Adv 2:2811-2813
Miannay, Bertrand; Minvielle, Stéphane; Magrangeas, Florence et al. (2018) Constraints on signaling network logic reveal functional subgraphs on Multiple Myeloma OMIC data. BMC Syst Biol 12:32

Showing the most recent 10 out of 218 publications